OTCPK:IMRS.Q

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has IMRIS's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMRS.Q's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

IMRS.Q

-2.5%

US Medical Equipment

-3.1%

US Market


1 Year Return

19,900.0%

IMRS.Q

14.6%

US Medical Equipment

12.7%

US Market

Return vs Industry: IMRS.Q exceeded the US Medical Equipment industry which returned 14.6% over the past year.

Return vs Market: IMRS.Q exceeded the US Market which returned 12.7% over the past year.


Shareholder returns

IMRS.QIndustryMarket
7 Day0%-2.5%-3.1%
30 Day100.0%-0.06%-2.9%
90 Day19,900.0%13.9%8.2%
1 Year19,900.0%19,900.0%15.6%14.6%15.3%12.7%
3 Year-85.7%-85.7%71.4%67.0%37.8%28.5%
5 Year-96.0%-96.0%149.1%130.4%90.9%69.4%

Price Volatility Vs. Market

How volatile is IMRIS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is IMRIS undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether IMRIS is trading at an attractive price based on the cash flow it is expected to produce in the future. But as IMRIS has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine IMRIS's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through IMRIS regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is IMRIS forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IMRIS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine IMRIS's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access IMRIS's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has IMRIS performed over the past 5 years?

15.4%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, IMRIS has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • Examine IMRIS's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access IMRIS's filings and announcements here.
  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is IMRIS's financial position?


In this section we usually analyse IMRIS's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. IMRIS has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of IMRS.Q’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when IMRIS's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is IMRIS current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMRS.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMRS.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMRS.Q's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMRS.Q's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMRS.Q's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Andy Flanagan

4.58yrs

Tenure

Mr. Andrew M. Flanagan, also known as Andy, has been the Chief Executive Officer and President at IMRIS, Inc. since February 22, 2016 and serves as its Director. Mr. Flanagan served as Chief Executive Offi ...


Leadership Team

NamePositionTenureCompensationOwnership
Maurice Holloman
Executive Vice President of Operations - Customer Support & Customer Engineering4.33yrsUS$255.29kno data
Gregory Sorensen
Executive Chairman4.58yrsno datano data
Andrew Flanagan
CEO, President & Director4.58yrsno datano data
Chris Monnot
VP of Finance & Controllerno datano datano data
David Clark
General Counsel & Director2.67yrsno datano data
Robert Korn
Senior Vice President of Global Sales and Marketing3.5yrsno datano data
Steven Swanson
Executive Board Member2.83yrsno datano data
Peter Simpson
Senior Vice President of Research & Development2.67yrsno datano data
Steven Hochberg
Executive Board Memberno datano datano data

3.7yrs

Average Tenure

58yo

Average Age

Experienced Management: IMRS.Q's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gregory Sorensen
Executive Chairman4.58yrsno datano data
Andrew Flanagan
CEO, President & Director4.58yrsno datano data
David Clark
General Counsel & Director2.67yrsno datano data
Steven Swanson
Executive Board Member2.83yrsno datano data
Steven Hochberg
Executive Board Memberno datano datano data
Vipul Patel
Member of SYMBIS Advisory Board7yrsno datano data
Garnette Sutherland
Member of SYMBIS Advisory Board7.33yrsno datano data
David Roberts
Member of SYMBIS Advisory Board7.33yrsno datano data
Melvin Field
Member of SYMBIS Advisory Board7.33yrsno datano data

7.0yrs

Average Tenure

Experienced Board: IMRS.Q's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

IMRIS Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IMRIS Inc.
  • Ticker: IMRS.Q
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$12.518k
  • Shares outstanding: 62.59m
  • Website: https://www.imris.com

Number of Employees


Location

  • IMRIS Inc.
  • 100-1370 Sony Place
  • Winnipeg
  • Manitoba
  • R3T 1N5
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMRS.QOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2007

Biography

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 06:26
End of Day Share Price2020/09/18 00:00
Earnings2014/12/31
Annual Earnings2014/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.